Cytek Biosciences Reports Third Quarter 2024 Financial Results
Cytek Biosciences, Inc. (CTKB)
Company Research
Source: GlobeNewswire
FREMONT, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year-to-date revenue of $143.0 million at September 30, 2024 was 6% above the same 9 month period in 2023 Launched SpectroPanel™ tool, a proprietary new intelligent algorithm which suggests optimized panels in minutes, expanding the capabilities of the Panel Builder tool within the Cytek® Cloud digital ecosystem Expanded to a total installed base of 2,821 Cytek instruments, including the Amnis® and Guava® instruments shipped since the acquisition of the flow cytometry and imaging business from Luminex Corporation in February 2023, adding 164 units
Show less
Read more
Impact Snapshot
Event Time:
CTKB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTKB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTKB alerts
High impacting Cytek Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CTKB
News
- Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramGlobeNewswire
- Cytek Biosciences, Inc. (NASDAQ: CTKB) had its price target raised by analysts at Piper Sandler from $8.00 to $8.50. They now have an "overweight" rating on the stock.MarketBeat
- Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterGlobeNewswire
- Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
CTKB
Earnings
- 11/5/24 - Beat
CTKB
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- CTKB's page on the SEC website